報價延遲最少15分鐘:2025/06/28 13:09 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
78.21 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
7.00/2.71
|
|
企業價值
45.93B
|
| 資產負債 |
|
每股賬面淨值
17.27
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
5.44B
|
|
每股收益
9.92
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/28 13:09 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |